In another trial (ATLANTIC) with 444 NSCLC patients enrolled in three cohorts, it was found that the proportion of patients with EGFR−/ALK− NSCLC achieving a response was higher than that with EGFR+/ALK+ NSCLC, nevertheless durvalumab activity was observed in patients with EGFR+ NSCLC whose tumor has ≥25% PD-L1 expression [27]. The gene discussed is ALK; the disease is neoplasm.